Matthew T. David, Interim CEO and CFO at CorMedix Inc. (CRMD), bought 1,000 shares at $4.50 ($5K) on 2021-12-06, disclosed to the SEC on 2021-12-07.
Open-market purchase of $4k CRMD by Interim CEO and CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |